Does Tigecycline Raise Liver Enzymes?
Tigecycline, an intravenous glycylcycline antibiotic used for complicated infections, commonly elevates liver enzymes like ALT and AST. In clinical trials, 20-30% of patients experienced these increases, typically mild to moderate and reversible after stopping the drug. Severe cases (ALT >10x upper limit of normal) occurred in under 1% of patients.[1][2]
How Often and How High Do Elevations Occur?
- Frequency: ALT elevations in 25-29% of tigecycline-treated patients vs. 15-20% in comparators; AST in 24-27% vs. 17-22%.[2]
- Severity: Most stay below 5x ULN; peaks often within 7-14 days of starting therapy.[3]
- Post-marketing data: Rare reports of liver injury, including cholestatic patterns, sometimes with jaundice or failure in patients with risk factors like fatty liver or alcohol use.[1]
Why Does Tigecycline Affect the Liver?
It inhibits bacterial protein synthesis but shows dose-dependent hepatotoxicity in animal models and humans, possibly via mitochondrial disruption or oxidative stress. No direct metabolite causes this; it's linked to the parent drug. Risk rises with prolonged use (>14 days) or higher doses.[2][4]
Who Is at Higher Risk?
Patients with pre-existing liver disease, obesity, diabetes, or concomitant hepatotoxins (e.g., acetaminophen, statins) see amplified effects. No clear genetic predictors identified. Monitor closely in ICU settings where tigecycline is common for resistant infections.[1][3]
What Happens If Enzymes Spike?
Discontinue if ALT/AST >5x ULN with symptoms (nausea, jaundice) or >10x ULN regardless. Enzymes normalize in 1-4 weeks off therapy in 90%+ cases. No evidence of chronic damage from short courses.[2][4]
How Does Monitoring Work in Practice?
Baseline LFTs required before starting; check weekly or more if abnormal. FDA label advises against use in severe hepatic impairment (Child-Pugh C).[1] Guidelines (IDSA) recommend tigecycline for multidrug-resistant bugs but flag hepatic monitoring.[5]
Alternatives for Liver-Concerned Patients?
Meropenem or colistin for similar infections have lower hepatic risk (ALT rise <10%). Newer options like eravacycline show similar but potentially milder profiles in trials.[3][6]
Sources
[1]: Tygacil (tigecycline) Prescribing Information - Pfizer
[2]: Tigecycline Clinical Safety Review - FDA
[3]: LiverTox: Tigecycline - NIH
[4]: Hepatotoxicity of Tigecycline - J Antimicrob Chemother (2018)
[5]: IDSA Guidelines for Complicated Infections
[6]: Eravacycline vs Tigecycline - Clin Infect Dis (2021)